Improved prognostic stratification using NCCN- and GELTAMOinternational prognostic index in patients with diffuse large B-cell lymphoma

Junshik Hong, Seok Jin Kim, Myung Hee Chang, Jeong A. Kim, Jae Yong Kwak, Jin Seok Kim, Dok Hyun Yoon, Won Sik Lee, Young Rok Do, Hye Jin Kang, Hyeon Seok Eom, Yong Park, Jong Ho Won, Yeung Chul Mun, Hyo Jung Kim, Jung Hye Kwon, Jee Hyun Kong, Sung Yong Oh, Sunah Lee, Sung Hwa BaeDeok Hwan Yang, Hyun Jung Jun, Ho Sup Lee, Hwan Jung Yun, Soon Il Lee, Min Kyoung Kim, Jun Ho Yi, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula ósea)-IPI were developed to enable better risk prediction of patients with diffuse large B-cell lymphoma (DLBCL). The present study compared the effectiveness of risk prediction between IPI, NCCN-IPI, and GELTAMO-IPI in patients with DLBCL particularly in terms of determining high-risk patients. Among 439 patients who were enrolled to a prospective DLBCL cohort treated with R-CHOP immunochemotherapy, risk groups were classified according to the three IPIs and the prognostic significance of individual IPI factors and IPI models were analyzed and compared. All three IPI effectively separated the analyzed patients into four risk groups according to overall survival (OS). Estimated 5-year OS of patients classified as high-risk according to the IPI was 45.7%, suggesting that the IPI is limited in the selection of patients who are expected to have a poor outcome. In contrast, the 5-year OS of patients stratified as high-risk according to NCCN- and GELTAMO-IPI was 31.4% and 21.9%, respectively. The results indicate that NCCN- and GELTAMO-IPI are better than the IPI in predicting patients with poor prognosis, suggesting the superiority of enhanced, next-generation IPIs for DLBCL.

Original languageEnglish
Pages (from-to)92171-92182
Number of pages12
JournalOncotarget
Volume8
Issue number54
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Neoplasms
Survival
Oceans and Seas
Patient Selection

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Hong, Junshik ; Kim, Seok Jin ; Chang, Myung Hee ; Kim, Jeong A. ; Kwak, Jae Yong ; Kim, Jin Seok ; Yoon, Dok Hyun ; Lee, Won Sik ; Do, Young Rok ; Kang, Hye Jin ; Eom, Hyeon Seok ; Park, Yong ; Won, Jong Ho ; Mun, Yeung Chul ; Kim, Hyo Jung ; Kwon, Jung Hye ; Kong, Jee Hyun ; Oh, Sung Yong ; Lee, Sunah ; Bae, Sung Hwa ; Yang, Deok Hwan ; Jun, Hyun Jung ; Lee, Ho Sup ; Yun, Hwan Jung ; Lee, Soon Il ; Kim, Min Kyoung ; Yi, Jun Ho ; Lee, Jae Hoon ; Kim, Won Seog ; Suh, Cheolwon. / Improved prognostic stratification using NCCN- and GELTAMOinternational prognostic index in patients with diffuse large B-cell lymphoma. In: Oncotarget. 2017 ; Vol. 8, No. 54. pp. 92171-92182.
@article{415526ca44184328a6ed124b5e5704b9,
title = "Improved prognostic stratification using NCCN- and GELTAMOinternational prognostic index in patients with diffuse large B-cell lymphoma",
abstract = "The National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and GELTAMO (Grupo Espa{\~n}ol de Linfomas/Trasplante Aut{\'o}logo de M{\'e}dula {\'o}sea)-IPI were developed to enable better risk prediction of patients with diffuse large B-cell lymphoma (DLBCL). The present study compared the effectiveness of risk prediction between IPI, NCCN-IPI, and GELTAMO-IPI in patients with DLBCL particularly in terms of determining high-risk patients. Among 439 patients who were enrolled to a prospective DLBCL cohort treated with R-CHOP immunochemotherapy, risk groups were classified according to the three IPIs and the prognostic significance of individual IPI factors and IPI models were analyzed and compared. All three IPI effectively separated the analyzed patients into four risk groups according to overall survival (OS). Estimated 5-year OS of patients classified as high-risk according to the IPI was 45.7{\%}, suggesting that the IPI is limited in the selection of patients who are expected to have a poor outcome. In contrast, the 5-year OS of patients stratified as high-risk according to NCCN- and GELTAMO-IPI was 31.4{\%} and 21.9{\%}, respectively. The results indicate that NCCN- and GELTAMO-IPI are better than the IPI in predicting patients with poor prognosis, suggesting the superiority of enhanced, next-generation IPIs for DLBCL.",
author = "Junshik Hong and Kim, {Seok Jin} and Chang, {Myung Hee} and Kim, {Jeong A.} and Kwak, {Jae Yong} and Kim, {Jin Seok} and Yoon, {Dok Hyun} and Lee, {Won Sik} and Do, {Young Rok} and Kang, {Hye Jin} and Eom, {Hyeon Seok} and Yong Park and Won, {Jong Ho} and Mun, {Yeung Chul} and Kim, {Hyo Jung} and Kwon, {Jung Hye} and Kong, {Jee Hyun} and Oh, {Sung Yong} and Sunah Lee and Bae, {Sung Hwa} and Yang, {Deok Hwan} and Jun, {Hyun Jung} and Lee, {Ho Sup} and Yun, {Hwan Jung} and Lee, {Soon Il} and Kim, {Min Kyoung} and Yi, {Jun Ho} and Lee, {Jae Hoon} and Kim, {Won Seog} and Cheolwon Suh",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20988",
language = "English",
volume = "8",
pages = "92171--92182",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "54",

}

Hong, J, Kim, SJ, Chang, MH, Kim, JA, Kwak, JY, Kim, JS, Yoon, DH, Lee, WS, Do, YR, Kang, HJ, Eom, HS, Park, Y, Won, JH, Mun, YC, Kim, HJ, Kwon, JH, Kong, JH, Oh, SY, Lee, S, Bae, SH, Yang, DH, Jun, HJ, Lee, HS, Yun, HJ, Lee, SI, Kim, MK, Yi, JH, Lee, JH, Kim, WS & Suh, C 2017, 'Improved prognostic stratification using NCCN- and GELTAMOinternational prognostic index in patients with diffuse large B-cell lymphoma', Oncotarget, vol. 8, no. 54, pp. 92171-92182. https://doi.org/10.18632/oncotarget.20988

Improved prognostic stratification using NCCN- and GELTAMOinternational prognostic index in patients with diffuse large B-cell lymphoma. / Hong, Junshik; Kim, Seok Jin; Chang, Myung Hee; Kim, Jeong A.; Kwak, Jae Yong; Kim, Jin Seok; Yoon, Dok Hyun; Lee, Won Sik; Do, Young Rok; Kang, Hye Jin; Eom, Hyeon Seok; Park, Yong; Won, Jong Ho; Mun, Yeung Chul; Kim, Hyo Jung; Kwon, Jung Hye; Kong, Jee Hyun; Oh, Sung Yong; Lee, Sunah; Bae, Sung Hwa; Yang, Deok Hwan; Jun, Hyun Jung; Lee, Ho Sup; Yun, Hwan Jung; Lee, Soon Il; Kim, Min Kyoung; Yi, Jun Ho; Lee, Jae Hoon; Kim, Won Seog; Suh, Cheolwon.

In: Oncotarget, Vol. 8, No. 54, 01.01.2017, p. 92171-92182.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improved prognostic stratification using NCCN- and GELTAMOinternational prognostic index in patients with diffuse large B-cell lymphoma

AU - Hong, Junshik

AU - Kim, Seok Jin

AU - Chang, Myung Hee

AU - Kim, Jeong A.

AU - Kwak, Jae Yong

AU - Kim, Jin Seok

AU - Yoon, Dok Hyun

AU - Lee, Won Sik

AU - Do, Young Rok

AU - Kang, Hye Jin

AU - Eom, Hyeon Seok

AU - Park, Yong

AU - Won, Jong Ho

AU - Mun, Yeung Chul

AU - Kim, Hyo Jung

AU - Kwon, Jung Hye

AU - Kong, Jee Hyun

AU - Oh, Sung Yong

AU - Lee, Sunah

AU - Bae, Sung Hwa

AU - Yang, Deok Hwan

AU - Jun, Hyun Jung

AU - Lee, Ho Sup

AU - Yun, Hwan Jung

AU - Lee, Soon Il

AU - Kim, Min Kyoung

AU - Yi, Jun Ho

AU - Lee, Jae Hoon

AU - Kim, Won Seog

AU - Suh, Cheolwon

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula ósea)-IPI were developed to enable better risk prediction of patients with diffuse large B-cell lymphoma (DLBCL). The present study compared the effectiveness of risk prediction between IPI, NCCN-IPI, and GELTAMO-IPI in patients with DLBCL particularly in terms of determining high-risk patients. Among 439 patients who were enrolled to a prospective DLBCL cohort treated with R-CHOP immunochemotherapy, risk groups were classified according to the three IPIs and the prognostic significance of individual IPI factors and IPI models were analyzed and compared. All three IPI effectively separated the analyzed patients into four risk groups according to overall survival (OS). Estimated 5-year OS of patients classified as high-risk according to the IPI was 45.7%, suggesting that the IPI is limited in the selection of patients who are expected to have a poor outcome. In contrast, the 5-year OS of patients stratified as high-risk according to NCCN- and GELTAMO-IPI was 31.4% and 21.9%, respectively. The results indicate that NCCN- and GELTAMO-IPI are better than the IPI in predicting patients with poor prognosis, suggesting the superiority of enhanced, next-generation IPIs for DLBCL.

AB - The National Comprehensive Cancer Network (NCCN)-International Prognostic Index (IPI) and GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula ósea)-IPI were developed to enable better risk prediction of patients with diffuse large B-cell lymphoma (DLBCL). The present study compared the effectiveness of risk prediction between IPI, NCCN-IPI, and GELTAMO-IPI in patients with DLBCL particularly in terms of determining high-risk patients. Among 439 patients who were enrolled to a prospective DLBCL cohort treated with R-CHOP immunochemotherapy, risk groups were classified according to the three IPIs and the prognostic significance of individual IPI factors and IPI models were analyzed and compared. All three IPI effectively separated the analyzed patients into four risk groups according to overall survival (OS). Estimated 5-year OS of patients classified as high-risk according to the IPI was 45.7%, suggesting that the IPI is limited in the selection of patients who are expected to have a poor outcome. In contrast, the 5-year OS of patients stratified as high-risk according to NCCN- and GELTAMO-IPI was 31.4% and 21.9%, respectively. The results indicate that NCCN- and GELTAMO-IPI are better than the IPI in predicting patients with poor prognosis, suggesting the superiority of enhanced, next-generation IPIs for DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=85032686702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032686702&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20988

DO - 10.18632/oncotarget.20988

M3 - Article

AN - SCOPUS:85032686702

VL - 8

SP - 92171

EP - 92182

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 54

ER -